INTRODUCTION
With the changing demographics of an aging population, polypharmacy has become an increasingly pertinent issue in clinical practice [1] [2] [3] [4] [5] [6] . In the literature, polypharmacy has been defined as the use of multiple drugs and of more drugs than clinically indicated. Despite the differences in definition, authors generally agree that the prevalence of polypharmacy has increased dramatically in recent decades and continues to increase [1] [2] [3] [4] [5] [6] . Analyses of nationally representative surveys from the Swedish Panel Study of Living Conditions of the Oldest Old found that polypharmacy rates more than doubled to 46% in 2002 from 18% in 1992 6 . Likewise, a large study of elderly subjects (≥65 years of age) in Italy demonstrated that 46% were exposed to polypharmacy 7 .
With the introduction of new and more complex medications, polypharmacy will become increasingly common, elevating the risk for potential drug interactions (pdis) 8, 9 . Because the risk of drug interactions can vary significantly based on patient characteristics such as age 4, 7, 10 , sex 11 , and body composition 4 , and on medication characteristics such as the number and types of drugs being used 7, 9, 12, 13 , pdis can be difficult to screen for and to detect, underscoring the need to develop ways of identifying high-risk individuals.
Several large studies have explored polypharmacy and pdis in the general population 6, 7 , but a literature search yielded no studies making similar direct comparisons in cancer survivors (css) and non-cancer patients. Prior studies evaluating drug interactions in css have been relatively small 9, [14] [15] [16] , localized to single
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Background
Cancer survivors (css) are frequently exposed to polypharmacy, which might increase their risk of drug interactions. Our study aimed to determine the relative prevalence of potential drug interactions (pdis) among css compared with non-cancer respondents (ncrs).
Methods
Self-reported prescription data from 4975 patients were extracted from the U.S. National Health and Nutrition Examination Survey and screened for pdis using iFacts: Drug Interaction Facts (Facts and Comparisons, St. Louis, MO, U.S.A.). The clinical significance of each pdi was graded on a 5-point scale based on the severity of the interaction and the level of evidence documenting the interaction. Summary statistics and logistic regression models were used to assess the impact of cancer history on the risk of pdis.
Results
Of patients eligible for the analyses, the css (n = 302) indicated using 4.4 ± 0.22 prescriptions on average, and the ncrs (n = 908), 3.8 ± 0.09. Nearly half of both cohorts (40% of css, 43% of ncrs) had at least 1 pdi. In both cohorts, 12% were at risk for fatal or permanently debilitating effects. In multivariate analyses, css were significantly less likely than ncrs to be at risk for any pdis (odds ratio: 0.65; 95% confidence interval: 0.46 to 0.92; p = 0.02). Advanced age and low household income were associated with pdis among css. Medications most commonly prescribed to css with a pdi included metoprolol (15.6%), levothyroxine (13.6%), and furosemide (11.9%).
Conclusions
Although css appear to be less susceptible than ncrs to pdis, the prevalence of pdis among css remains centres or institutions 14, 15 , or unable to compare css with controls [14] [15] [16] . Importantly, css constitute a patient group that is highly vulnerable to pdis for several reasons. First, prior or ongoing anticancer treatments can result in side effects that limit the repertoire of drugs that might otherwise be considered safe and available in non-cancer patients 9, 12, [17] [18] [19] . Second, many css are elderly, and altered drug metabolism in this age group might make them more susceptible to adverse drug interactions 10, 19, 20 . Third, css frequently take concomitant prescription and overthe-counter (otc) medications for the management of either other comorbidities or late toxicities from anticancer therapies 9, 17, 19, 21, 22 . For instance, one U.S. study of css found that 96% consumed at least 1 prescription drug, and 71%, at least 1 otc drug, 3 days before their chemotherapy 23 . Another analysis observed that 2% of unplanned hospital visits by css were secondary to drug interactions 24 . That finding likely underestimates the true frequency, because concomitant complaints and symptoms at the time of medical presentation might lead clinicians to attribute a hospital visit to a cause other than drug interaction. Despite those observations, only a few studies have directly compared the rate of pdis in css and non-cancer patients.
METHODS
Data Source and Study Cohort
The data used in our analyses were acquired from the U.S. population-based National Health and Nutrition Examination Survey (nhanes). Specifically, nhanes is a cross-sectional, nationally representative survey conducted biennially in participants' homes in conjunction with well-equipped mobile medical centres designed to assess the health and nutrition status of adults in the United States. The survey consists of an in-person interview component that collects self-reported patient demographics, general health information, and socioeconomic and dietary status, and a clinical component that consists of medical, physiologic, and laboratory measurements taken by trained professionals. The nhanes has been approved by the U.S. National Center for Health Statistics and obtains informed consent from all participants. Our cohort was limited to participants 18-85 years of age at the time of the study. Respondents whose questionnaire reported ever having cancer were classified as css. They were compared with non-cancer respondents (ncrs) who denied having any history of a prior or current cancer diagnosis.
Study Inclusion Criteria
Prescriptions from the 2007-2008 nhanes were self-reported by participants and were included in the present analysis only if survey respondents provided either the drug name or drug container to the examiner. Because the analysis used a screening program for pdis, only patients with at least 2 recorded prescriptions recognized by our screening program were considered.
Definition of Polypharmacy and PDI
Participants in nhanes are specifically asked to describe all of their current prescription medications. For the purposes of our study, polypharmacy was considered to be the use of 2 or more prescription drugs. To screen for pdis, the names of the medications self-reported by each respondent were manually entered into a specialized software program called iFacts: Drug Interaction Facts (version 13.10: Facts and Comparisons, St. Louis, MO, U.S.A.) 15, 23 . The iFacts program is designed to identify the presence of pdis; it also evaluates the "significance" of all pdis on a 5-point scale (Table i) , which takes into consideration the level of severity and the amount of scientific evidence supporting the specific interaction. The severity level was graded as major (effects could cause permanent damage or death), moderate (effects could worsen clinical status and potentially require intervention or hospitalization), or minor (effects, if any, are mild and generally will not require intervention). The evidence level was categorized into established (proven to occur in clinical studies), probable (very likely, but not yet clinically proven), suspected (supported by good data, but requires further study), possible (limited data, but could occur), or unlikely (possible, but lacks good supporting evidence).
Description of the Covariates
Demographic features and socioeconomic characteristics of css were compared with those of the ncrs. We analyzed various demographic features, including age, sex, ethnicity, and time lived in the United States. Specifically, age was dichotomized into less than or 60 or more years of age, and ethnicity was classified as Hispanic, non-Hispanic white, non-Hispanic black, and other races (including multiracial). Time lived in the United States was 
Statistical Considerations
All statistical analyses were performed using Stata 11.0 (StataCorp LP, College Station, TX, U.S.A.). Appropriate survey weighting algorithms provided by nhanes were applied to all of the univariate analyses and multivariate regression models to account for sampling errors, nonresponses, and the overall complex survey design. Trends reported in the present study are therefore statistically representative of the U.S. population. Baseline characteristics are reported as weighted proportions for categorical variables and as weighted means for continuous variables. The chi-square and t-tests were used to test significance in univariate analyses. Multinomial logistic regression models were constructed, and odds ratios (ors) and 95% confidence intervals (cis) were used to describe how a prior or current diagnosis of cancer or other clinical characteristics were associated with the risk for each of the following outcomes: any pdi; an established pdi; and severe pdi. A p value of 0.05 was considered significant in all of our statistical comparisons. The Wald test was used in the regression models to derive global p values.
RESULTS
Baseline Characteristics of the Study Cohort
The 1210 nhanes participants eligible for the present study included 302 css (25.0%) and 908 ncrs (75.0%). The css tended to be slightly older (mean age: 70.2 years vs. 68.3 years for the ncrs, p = 0.03) and were more likely to be of white ethnicity (80.1% vs. 63.2%, p = 0.04). Otherwise, most members of both the cs and ncr groups were women (54.0% vs. 58.7%, p = 0.81), married (60.3% vs. 54.6%, p = 0.48), had not completed college (76.9% vs. 82.8%, p = 0.45), and earned more than $20,000 annually (72.5% vs. 71.5%, p = 0.33). Table ii summarizes additional details of the baseline characteristics of the css and ncrs.
Patterns of Polypharmacy and PDIs
The cs group reported a significantly higher mean number of prescriptions (4.4 vs. 3.8 for the ncr group, p = 0.01, Table iii), although the difference did not persist once both groups were controlled for other factors (p = 0.16, Table iv ). Most of the study cohort did not have a pdi (57.5% for css vs. 55.3% for ncrs), but a fair number of patients still had a medication profile that posed a potential risk for interaction that ranked as high as grade 1 or 2 on the significance rating scale (grade 1: 15.6% css vs. 11.5% ncrs; grade 2: 13.9% css vs. 14.7% ncrs). However, the overall risk for these pdis appeared to be similar for the css and ncrs (p = 0.43). Likewise, in terms of the severity of the potential interactions, a fair number were classified as major (13.0% css vs. 12.2% ncrs) or moderate (24.6% vs. 26.1%), although the distribution of severity was similar in the groups (p = 0.44). 
Risk Factors Associated with Medication Use and Interactions
DISCUSSION
In the present study, we hypothesized that data from nhanes 2007-2008 would show css to be at greater risk for pdis because they are more inclined to take a higher number of cancer-related and non-cancerrelated medications. On the contrary, we found that css were not at any higher risk than their non-cancer counterparts. In our univariate analyses, css showed similar levels of pdis despite reporting significantly more prescriptions. Our multivariate model further demonstrated that cancer status was not independently associated with polypharmacy; rather, a prior cancer history was independently correlated with a reduced risk of both major and minor pdi.
These unexpected findings might in part be attributable to the emerging multi-and interdisciplinary nature of cancer care in the United States, in which cancer centres often have highly integrated health care teams that provide channels for close communication between oncologists, pharmacists, and family physicians. This type of practice setting has been demonstrated to improve the management of concomitant medications for patients [25] [26] [27] . Because of the severity of the toxicities that can result from many cancer treatments, cancer care providers might also be more vigilant in evaluating medication histories for css and thus more inclined to actively screen for pdis on a regular basis than during the management of non-cancer patients 28, 29 .
The risk of pdis was not particularly elevated among css compared with ncrs, but the absolute prevalence of pdis remains suboptimal in both groups of patients (44.7% and 42.5% respectively). Additionally, the prevalence of pdis that are associated with permanent, debilitating, or fatal side effects was 13.0% for css and 12.2% for ncrs. Our results showed that elderly patients (≥60 years of age as an independent risk factor) were not particularly susceptible to pdis; however, they were highly exposed to polypharmacy. Because polypharmacy was the strongest predictor for increased risk of pdi in our analysis, we suggest that the high exposure of older patients to drug interactions can largely be attributed to the number of drugs they take. Indeed, one of our more alarming findings was that patients taking more than 5 prescriptions had odds for being exposed to a pdi that was higher by a factor of 47 compared to patients taking 2-3 prescriptions. Those findings corroborate results in another study in geriatric css (70-90 years of age), which found that patients were taking an average of 9.1 prescriptions 30 . As the U.S. population continues to age, the number of elderly patients who will be diagnosed with cancer is expected to steadily increase, thus making polypharmacy and pdis particularly pertinent issues in the care of future css.
Our analyses also revealed that a high annual household income was associated with a decreased risk of polypharmacy. Although a number of studies have explored the role of medical and socioeconomic factors and their effects on medication use and adherence, the impact of income on polypharmacy has not been as well described in the literature. One of the few studies in the area found that poor income levels were associated with lower self-perceived health and more comorbidities 31 . That association might be one possible explanation for the association of more prescriptions with lower income in our study cohort.
Many earlier studies showed an increased susceptibility of css to drug interactions and polypharmacy. Those studies frequently found that css were older, more likely to report taking multiple concomitant medications to treat cancer and its associated symptoms, and more inclined to experience greater treatment-induced toxicities and more comorbid conditions. One such study screened hospitalized cancer patients and detected 180 potential drug interactions in 63% of its patients 15 . However, almost all of the studies were descriptive in nature and did not specifically compare rates of interactions and polypharmacy with those observed in a similar non-cancer population. Thus, one of the strengths of the present analysis is its comparisons of medication profiles in css and ncrs participating in nhanes, which is weighted in such a manner that results are representative of the U.S. population.
Medication profiles for the respondents included in our study who were at high risk for pdis were similar in the css and ncrs: 9 of the 10 drugs most commonly implicated for a pdi in css were also among the drugs most frequently prescribed to ncrs. The most prominent category of drugs included those prescribed for treatment of hypertension, angina, and peripheral edema (for example, metoprolol, lisinopril, amlodipine, furosemide, and hydrochlorothiazide)-a finding that is expected, given that those medications represent drugs that are very commonly used in the general population. Statins-including atorvastatin and simvastatin-are another class of drugs heavily implicated in potential interactions. We also observed that warfarin was most frequently associated with potential interactions of the greatest severity. That finding is not surprising, given that warfarin is a potent anticoagulant and that many drugs can affect its absorption or metabolism. Our list of offending drugs (Table vi) should be considered by physicians so that they can be vigilant about pdis whenever those drugs are prescribed to their patients.
Our study has several limitations. First, nhanes included only self-reported prescriptions or prescriptions for which labelled bottles were provided to survey staff, which might have biased the survey toward underreporting of specific prescriptions. Furthermore, herbal products and otc medications were not collected, and so we could not reliably describe or analyze potential interactions that involve those classes of drugs. Moreover, our analysis exploring pdis used data from a cross-sectional survey within a particular time period. We therefore cannot comment on temporal patterns in pdis. Future studies should investigate how medication patterns and polypharmacy might be changing over time. Finally, pdis might not actually represent medication interactions that truly require medical attention. However, pdis are admittedly difficult to study because serious adverse events from drugs are typically rare, thus necessitating assembly of a large longitudinal cohort.
CONCLUSIONS
Our study demonstrated that polypharmacy and pdis remain prevalent problems for both css and ncrs. To better manage concomitant medications in these two patient populations, Sokol et al. 30 offered these recommendations:
• routine reassessment of all prescriptions, otcs, and herbal products; and • communication of a complete list of medications between health care providers on every referral, hospital admission, hospital transfer, and hospital discharge.
Similar suggestions and guidelines have been proposed by geriatric and supportive care associations 27, 28, [32] [33] [34] [35] [36] [37] . For those reasons, a concerted effort should be made to incorporate those recommendations into routine clinical practice for both css and elderly patients in general. 
